Table of Content

1 Glutamate Antagonist Market Overview
1.1 Product Overview and Scope of Glutamate Antagonist
1.2 Glutamate Antagonist Segment by Type
1.2.1 Global Glutamate Antagonist Market Value Comparison by Type (2024-2034)
1.2.2 Ionic
1.2.3 Non Ionic
1.3 Glutamate Antagonist Segment by Application
1.3.1 Global Glutamate Antagonist Market Value by Application: (2024-2034)
1.3.2 Hospitals
1.3.3 Clinics
1.3.4 Laboratory
1.3.5 Others
1.4 Global Glutamate Antagonist Market Size Estimates and Forecasts
1.4.1 Global Glutamate Antagonist Revenue 2018-2029
1.4.2 Global Glutamate Antagonist Sales 2018-2029
1.4.3 Global Glutamate Antagonist Market Average Price (2018-2029)
1.5 Assumptions and Limitations
2 Glutamate Antagonist Market Competition by Manufacturers
2.1 Global Glutamate Antagonist Sales Market Share by Manufacturers (2018-2024)
2.2 Global Glutamate Antagonist Revenue Market Share by Manufacturers (2018-2024)
2.3 Global Glutamate Antagonist Average Price by Manufacturers (2018-2024)
2.4 Global Glutamate Antagonist Industry Ranking 2021 VS 2022 VS 2024
2.5 Global Key Manufacturers of Glutamate Antagonist, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Glutamate Antagonist, Product Type & Application
2.7 Glutamate Antagonist Market Competitive Situation and Trends
2.7.1 Glutamate Antagonist Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Glutamate Antagonist Players Market Share by Revenue
2.7.3 Global Glutamate Antagonist Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Glutamate Antagonist Retrospective Market Scenario by Region
3.1 Global Glutamate Antagonist Market Size by Region: 2018 Versus 2022 Versus 2029
3.2 Global Glutamate Antagonist Global Glutamate Antagonist Sales by Region: 2018-2029
3.2.1 Global Glutamate Antagonist Sales by Region: 2018-2024
3.2.2 Global Glutamate Antagonist Sales by Region: 2024-2029
3.3 Global Glutamate Antagonist Global Glutamate Antagonist Revenue by Region: 2018-2029
3.3.1 Global Glutamate Antagonist Revenue by Region: 2018-2024
3.3.2 Global Glutamate Antagonist Revenue by Region: 2024-2029
3.4 North America Glutamate Antagonist Market Facts & Figures by Country
3.4.1 North America Glutamate Antagonist Market Size by Country: 2018 VS 2022 VS 2029
3.4.2 North America Glutamate Antagonist Sales by Country (2018-2029)
3.4.3 North America Glutamate Antagonist Revenue by Country (2018-2029)
3.4.4 United States
3.4.5 Canada
3.5 Europe Glutamate Antagonist Market Facts & Figures by Country
3.5.1 Europe Glutamate Antagonist Market Size by Country: 2018 VS 2022 VS 2029
3.5.2 Europe Glutamate Antagonist Sales by Country (2018-2029)
3.5.3 Europe Glutamate Antagonist Revenue by Country (2018-2029)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Glutamate Antagonist Market Facts & Figures by Country
3.6.1 Asia Pacific Glutamate Antagonist Market Size by Country: 2018 VS 2022 VS 2029
3.6.2 Asia Pacific Glutamate Antagonist Sales by Country (2018-2029)
3.6.3 Asia Pacific Glutamate Antagonist Revenue by Country (2018-2029)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America Glutamate Antagonist Market Facts & Figures by Country
3.7.1 Latin America Glutamate Antagonist Market Size by Country: 2018 VS 2022 VS 2029
3.7.2 Latin America Glutamate Antagonist Sales by Country (2018-2029)
3.7.3 Latin America Glutamate Antagonist Revenue by Country (2018-2029)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Glutamate Antagonist Market Facts & Figures by Country
3.8.1 Middle East and Africa Glutamate Antagonist Market Size by Country: 2018 VS 2022 VS 2029
3.8.2 Middle East and Africa Glutamate Antagonist Sales by Country (2018-2029)
3.8.3 Middle East and Africa Glutamate Antagonist Revenue by Country (2018-2029)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Glutamate Antagonist Sales by Type (2018-2029)
4.1.1 Global Glutamate Antagonist Sales by Type (2018-2024)
4.1.2 Global Glutamate Antagonist Sales by Type (2024-2029)
4.1.3 Global Glutamate Antagonist Sales Market Share by Type (2018-2029)
4.2 Global Glutamate Antagonist Revenue by Type (2018-2029)
4.2.1 Global Glutamate Antagonist Revenue by Type (2018-2024)
4.2.2 Global Glutamate Antagonist Revenue by Type (2024-2029)
4.2.3 Global Glutamate Antagonist Revenue Market Share by Type (2018-2029)
4.3 Global Glutamate Antagonist Price by Type (2018-2029)
5 Segment by Application
5.1 Global Glutamate Antagonist Sales by Application (2018-2029)
5.1.1 Global Glutamate Antagonist Sales by Application (2018-2024)
5.1.2 Global Glutamate Antagonist Sales by Application (2024-2029)
5.1.3 Global Glutamate Antagonist Sales Market Share by Application (2018-2029)
5.2 Global Glutamate Antagonist Revenue by Application (2018-2029)
5.2.1 Global Glutamate Antagonist Revenue by Application (2018-2024)
5.2.2 Global Glutamate Antagonist Revenue by Application (2024-2029)
5.2.3 Global Glutamate Antagonist Revenue Market Share by Application (2018-2029)
5.3 Global Glutamate Antagonist Price by Application (2018-2029)
6 Key Companies Profiled
6.1 Artemis Neuroscience
6.1.1 Artemis Neuroscience Corporation Information
6.1.2 Artemis Neuroscience Description and Business Overview
6.1.3 Artemis Neuroscience Glutamate Antagonist Sales, Revenue and Gross Margin (2018-2024)
6.1.4 Artemis Neuroscience Glutamate Antagonist Product Portfolio
6.1.5 Artemis Neuroscience Recent Developments/Updates
6.2 VistaGen Therapeutics
6.2.1 VistaGen Therapeutics Corporation Information
6.2.2 VistaGen Therapeutics Description and Business Overview
6.2.3 VistaGen Therapeutics Glutamate Antagonist Sales, Revenue and Gross Margin (2018-2024)
6.2.4 VistaGen Therapeutics Glutamate Antagonist Product Portfolio
6.2.5 VistaGen Therapeutics Recent Developments/Updates
6.3 Rottapharm Madaus
6.3.1 Rottapharm Madaus Corporation Information
6.3.2 Rottapharm Madaus Description and Business Overview
6.3.3 Rottapharm Madaus Glutamate Antagonist Sales, Revenue and Gross Margin (2018-2024)
6.3.4 Rottapharm Madaus Glutamate Antagonist Product Portfolio
6.3.5 Rottapharm Madaus Recent Developments/Updates
6.4 Amorsa Therapeutics
6.4.1 Amorsa Therapeutics Corporation Information
6.4.2 Amorsa Therapeutics Description and Business Overview
6.4.3 Amorsa Therapeutics Glutamate Antagonist Sales, Revenue and Gross Margin (2018-2024)
6.4.4 Amorsa Therapeutics Glutamate Antagonist Product Portfolio
6.4.5 Amorsa Therapeutics Recent Developments/Updates
6.5 Newron Pharmaceuticals
6.5.1 Newron Pharmaceuticals Corporation Information
6.5.2 Newron Pharmaceuticals Description and Business Overview
6.5.3 Newron Pharmaceuticals Glutamate Antagonist Sales, Revenue and Gross Margin (2018-2024)
6.5.4 Newron Pharmaceuticals Glutamate Antagonist Product Portfolio
6.5.5 Newron Pharmaceuticals Recent Developments/Updates
6.6 Purdue Biopharma
6.6.1 Purdue Biopharma Corporation Information
6.6.2 Purdue Biopharma Description and Business Overview
6.6.3 Purdue Biopharma Glutamate Antagonist Sales, Revenue and Gross Margin (2018-2024)
6.6.4 Purdue Biopharma Glutamate Antagonist Product Portfolio
6.6.5 Purdue Biopharma Recent Developments/Updates
6.7 Relmada Therapeutics
6.6.1 Relmada Therapeutics Corporation Information
6.6.2 Relmada Therapeutics Description and Business Overview
6.6.3 Relmada Therapeutics Glutamate Antagonist Sales, Revenue and Gross Margin (2018-2024)
6.4.4 Relmada Therapeutics Glutamate Antagonist Product Portfolio
6.7.5 Relmada Therapeutics Recent Developments/Updates
6.8 BioCrea GmbH
6.8.1 BioCrea GmbH Corporation Information
6.8.2 BioCrea GmbH Description and Business Overview
6.8.3 BioCrea GmbH Glutamate Antagonist Sales, Revenue and Gross Margin (2018-2024)
6.8.4 BioCrea GmbH Glutamate Antagonist Product Portfolio
6.8.5 BioCrea GmbH Recent Developments/Updates
6.9 Cerecor Inc.
6.9.1 Cerecor Inc. Corporation Information
6.9.2 Cerecor Inc. Description and Business Overview
6.9.3 Cerecor Inc. Glutamate Antagonist Sales, Revenue and Gross Margin (2018-2024)
6.9.4 Cerecor Inc. Glutamate Antagonist Product Portfolio
6.9.5 Cerecor Inc. Recent Developments/Updates
6.10 NeurOp Inc.
6.10.1 NeurOp Inc. Corporation Information
6.10.2 NeurOp Inc. Description and Business Overview
6.10.3 NeurOp Inc. Glutamate Antagonist Sales, Revenue and Gross Margin (2018-2024)
6.10.4 NeurOp Inc. Glutamate Antagonist Product Portfolio
6.10.5 NeurOp Inc. Recent Developments/Updates
6.11 UCB SA
6.11.1 UCB SA Corporation Information
6.11.2 UCB SA Glutamate Antagonist Description and Business Overview
6.11.3 UCB SA Glutamate Antagonist Sales, Revenue and Gross Margin (2018-2024)
6.11.4 UCB SA Glutamate Antagonist Product Portfolio
6.11.5 UCB SA Recent Developments/Updates
6.12 Novartis AG
6.12.1 Novartis AG Corporation Information
6.12.2 Novartis AG Glutamate Antagonist Description and Business Overview
6.12.3 Novartis AG Glutamate Antagonist Sales, Revenue and Gross Margin (2018-2024)
6.12.4 Novartis AG Glutamate Antagonist Product Portfolio
6.12.5 Novartis AG Recent Developments/Updates
6.13 Luc Therapeutics Inc.
6.13.1 Luc Therapeutics Inc. Corporation Information
6.13.2 Luc Therapeutics Inc. Glutamate Antagonist Description and Business Overview
6.13.3 Luc Therapeutics Inc. Glutamate Antagonist Sales, Revenue and Gross Margin (2018-2024)
6.13.4 Luc Therapeutics Inc. Glutamate Antagonist Product Portfolio
6.13.5 Luc Therapeutics Inc. Recent Developments/Updates
6.14 Evotec AG
6.14.1 Evotec AG Corporation Information
6.14.2 Evotec AG Glutamate Antagonist Description and Business Overview
6.14.3 Evotec AG Glutamate Antagonist Sales, Revenue and Gross Margin (2018-2024)
6.14.4 Evotec AG Glutamate Antagonist Product Portfolio
6.14.5 Evotec AG Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Glutamate Antagonist Industry Chain Analysis
7.2 Glutamate Antagonist Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Glutamate Antagonist Production Mode & Process
7.4 Glutamate Antagonist Sales and Marketing
7.4.1 Glutamate Antagonist Sales Channels
7.4.2 Glutamate Antagonist Distributors
7.5 Glutamate Antagonist Customers
8 Glutamate Antagonist Market Dynamics
8.1 Glutamate Antagonist Industry Trends
8.2 Glutamate Antagonist Market Drivers
8.3 Glutamate Antagonist Market Challenges
8.4 Glutamate Antagonist Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer

List of Figure

List of Tables
Table 1. Global Glutamate Antagonist Market Value Comparison by Type (2024-2034) & (US$ Million)
Table 2. Global Glutamate Antagonist Market Value Comparison by Application (2024-2034) & (US$ Million)
Table 3. Global Glutamate Antagonist Market Competitive Situation by Manufacturers in 2022
Table 4. Global Glutamate Antagonist Sales (K Units) of Key Manufacturers (2018-2024)
Table 5. Global Glutamate Antagonist Sales Market Share by Manufacturers (2018-2024)
Table 6. Global Glutamate Antagonist Revenue (US$ Million) by Manufacturers (2018-2024)
Table 7. Global Glutamate Antagonist Revenue Share by Manufacturers (2018-2024)
Table 8. Global Market Glutamate Antagonist Average Price (US$/Unit) of Key Manufacturers (2018-2024)
Table 9. Global Key Players of Glutamate Antagonist, Industry Ranking, 2021 VS 2022 VS 2024
Table 10. Global Key Manufacturers of Glutamate Antagonist, Manufacturing Sites & Headquarters
Table 11. Global Key Manufacturers of Glutamate Antagonist, Product Type & Application
Table 12. Global Key Manufacturers of Glutamate Antagonist, Date of Enter into This Industry
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Glutamate Antagonist by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Glutamate Antagonist as of 2022)
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 16. Global Glutamate Antagonist Market Size by Region (US$ Million): 2018 VS 2022 VS 2029
Table 17. Global Glutamate Antagonist Sales by Region (2018-2024) & (K Units)
Table 18. Global Glutamate Antagonist Sales Market Share by Region (2018-2024)
Table 19. Global Glutamate Antagonist Sales by Region (2024-2029) & (K Units)
Table 20. Global Glutamate Antagonist Sales Market Share by Region (2024-2029)
Table 21. Global Glutamate Antagonist Revenue by Region (2018-2024) & (US$ Million)
Table 22. Global Glutamate Antagonist Revenue Market Share by Region (2018-2024)
Table 23. Global Glutamate Antagonist Revenue by Region (2024-2029) & (US$ Million)
Table 24. Global Glutamate Antagonist Revenue Market Share by Region (2024-2029)
Table 25. North America Glutamate Antagonist Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 26. North America Glutamate Antagonist Sales by Country (2018-2024) & (K Units)
Table 27. North America Glutamate Antagonist Sales by Country (2024-2029) & (K Units)
Table 28. North America Glutamate Antagonist Revenue by Country (2018-2024) & (US$ Million)
Table 29. North America Glutamate Antagonist Revenue by Country (2024-2029) & (US$ Million)
Table 30. Europe Glutamate Antagonist Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 31. Europe Glutamate Antagonist Sales by Country (2018-2024) & (K Units)
Table 32. Europe Glutamate Antagonist Sales by Country (2024-2029) & (K Units)
Table 33. Europe Glutamate Antagonist Revenue by Country (2018-2024) & (US$ Million)
Table 34. Europe Glutamate Antagonist Revenue by Country (2024-2029) & (US$ Million)
Table 35. Asia Pacific Glutamate Antagonist Revenue by Region: 2018 VS 2022 VS 2029 (US$ Million)
Table 36. Asia Pacific Glutamate Antagonist Sales by Region (2018-2024) & (K Units)
Table 37. Asia Pacific Glutamate Antagonist Sales by Region (2024-2029) & (K Units)
Table 38. Asia Pacific Glutamate Antagonist Revenue by Region (2018-2024) & (US$ Million)
Table 39. Asia Pacific Glutamate Antagonist Revenue by Region (2024-2029) & (US$ Million)
Table 40. Latin America Glutamate Antagonist Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 41. Latin America Glutamate Antagonist Sales by Country (2018-2024) & (K Units)
Table 42. Latin America Glutamate Antagonist Sales by Country (2024-2029) & (K Units)
Table 43. Latin America Glutamate Antagonist Revenue by Country (2018-2024) & (US$ Million)
Table 44. Latin America Glutamate Antagonist Revenue by Country (2024-2029) & (US$ Million)
Table 45. Middle East & Africa Glutamate Antagonist Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 46. Middle East & Africa Glutamate Antagonist Sales by Country (2018-2024) & (K Units)
Table 47. Middle East & Africa Glutamate Antagonist Sales by Country (2024-2029) & (K Units)
Table 48. Middle East & Africa Glutamate Antagonist Revenue by Country (2018-2024) & (US$ Million)
Table 49. Middle East & Africa Glutamate Antagonist Revenue by Country (2024-2029) & (US$ Million)
Table 50. Global Glutamate Antagonist Sales (K Units) by Type (2018-2024)
Table 51. Global Glutamate Antagonist Sales (K Units) by Type (2024-2029)
Table 52. Global Glutamate Antagonist Sales Market Share by Type (2018-2024)
Table 53. Global Glutamate Antagonist Sales Market Share by Type (2024-2029)
Table 54. Global Glutamate Antagonist Revenue (US$ Million) by Type (2018-2024)
Table 55. Global Glutamate Antagonist Revenue (US$ Million) by Type (2024-2029)
Table 56. Global Glutamate Antagonist Revenue Market Share by Type (2018-2024)
Table 57. Global Glutamate Antagonist Revenue Market Share by Type (2024-2029)
Table 58. Global Glutamate Antagonist Price (US$/Unit) by Type (2018-2024)
Table 59. Global Glutamate Antagonist Price (US$/Unit) by Type (2024-2029)
Table 60. Global Glutamate Antagonist Sales (K Units) by Application (2018-2024)
Table 61. Global Glutamate Antagonist Sales (K Units) by Application (2024-2029)
Table 62. Global Glutamate Antagonist Sales Market Share by Application (2018-2024)
Table 63. Global Glutamate Antagonist Sales Market Share by Application (2024-2029)
Table 64. Global Glutamate Antagonist Revenue (US$ Million) by Application (2018-2024)
Table 65. Global Glutamate Antagonist Revenue (US$ Million) by Application (2024-2029)
Table 66. Global Glutamate Antagonist Revenue Market Share by Application (2018-2024)
Table 67. Global Glutamate Antagonist Revenue Market Share by Application (2024-2029)
Table 68. Global Glutamate Antagonist Price (US$/Unit) by Application (2018-2024)
Table 69. Global Glutamate Antagonist Price (US$/Unit) by Application (2024-2029)
Table 70. Artemis Neuroscience Corporation Information
Table 71. Artemis Neuroscience Description and Business Overview
Table 72. Artemis Neuroscience Glutamate Antagonist Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 73. Artemis Neuroscience Glutamate Antagonist Product
Table 74. Artemis Neuroscience Recent Developments/Updates
Table 75. VistaGen Therapeutics Corporation Information
Table 76. VistaGen Therapeutics Description and Business Overview
Table 77. VistaGen Therapeutics Glutamate Antagonist Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 78. VistaGen Therapeutics Glutamate Antagonist Product
Table 79. VistaGen Therapeutics Recent Developments/Updates
Table 80. Rottapharm Madaus Corporation Information
Table 81. Rottapharm Madaus Description and Business Overview
Table 82. Rottapharm Madaus Glutamate Antagonist Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 83. Rottapharm Madaus Glutamate Antagonist Product
Table 84. Rottapharm Madaus Recent Developments/Updates
Table 85. Amorsa Therapeutics Corporation Information
Table 86. Amorsa Therapeutics Description and Business Overview
Table 87. Amorsa Therapeutics Glutamate Antagonist Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 88. Amorsa Therapeutics Glutamate Antagonist Product
Table 89. Amorsa Therapeutics Recent Developments/Updates
Table 90. Newron Pharmaceuticals Corporation Information
Table 91. Newron Pharmaceuticals Description and Business Overview
Table 92. Newron Pharmaceuticals Glutamate Antagonist Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 93. Newron Pharmaceuticals Glutamate Antagonist Product
Table 94. Newron Pharmaceuticals Recent Developments/Updates
Table 95. Purdue Biopharma Corporation Information
Table 96. Purdue Biopharma Description and Business Overview
Table 97. Purdue Biopharma Glutamate Antagonist Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 98. Purdue Biopharma Glutamate Antagonist Product
Table 99. Purdue Biopharma Recent Developments/Updates
Table 100. Relmada Therapeutics Corporation Information
Table 101. Relmada Therapeutics Description and Business Overview
Table 102. Relmada Therapeutics Glutamate Antagonist Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 103. Relmada Therapeutics Glutamate Antagonist Product
Table 104. Relmada Therapeutics Recent Developments/Updates
Table 105. BioCrea GmbH Corporation Information
Table 106. BioCrea GmbH Description and Business Overview
Table 107. BioCrea GmbH Glutamate Antagonist Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 108. BioCrea GmbH Glutamate Antagonist Product
Table 109. BioCrea GmbH Recent Developments/Updates
Table 110. Cerecor Inc. Corporation Information
Table 111. Cerecor Inc. Description and Business Overview
Table 112. Cerecor Inc. Glutamate Antagonist Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 113. Cerecor Inc. Glutamate Antagonist Product
Table 114. Cerecor Inc. Recent Developments/Updates
Table 115. NeurOp Inc. Corporation Information
Table 116. NeurOp Inc. Description and Business Overview
Table 117. NeurOp Inc. Glutamate Antagonist Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 118. NeurOp Inc. Glutamate Antagonist Product
Table 119. NeurOp Inc. Recent Developments/Updates
Table 120. UCB SA Corporation Information
Table 121. UCB SA Description and Business Overview
Table 122. UCB SA Glutamate Antagonist Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 123. UCB SA Glutamate Antagonist Product
Table 124. UCB SA Recent Developments/Updates
Table 125. Novartis AG Corporation Information
Table 126. Novartis AG Description and Business Overview
Table 127. Novartis AG Glutamate Antagonist Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 128. Novartis AG Glutamate Antagonist Product
Table 129. Novartis AG Recent Developments/Updates
Table 130. Luc Therapeutics Inc. Corporation Information
Table 131. Luc Therapeutics Inc. Description and Business Overview
Table 132. Luc Therapeutics Inc. Glutamate Antagonist Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 133. Luc Therapeutics Inc. Glutamate Antagonist Product
Table 134. Luc Therapeutics Inc. Recent Developments/Updates
Table 135. Evotec AG Corporation Information
Table 136. Evotec AG Description and Business Overview
Table 137. Evotec AG Glutamate Antagonist Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 138. Evotec AG Glutamate Antagonist Product
Table 139. Evotec AG Recent Developments/Updates
Table 140. Key Raw Materials Lists
Table 141. Raw Materials Key Suppliers Lists
Table 142. Glutamate Antagonist Distributors List
Table 143. Glutamate Antagonist Customers List
Table 144. Glutamate Antagonist Market Trends
Table 145. Glutamate Antagonist Market Drivers
Table 146. Glutamate Antagonist Market Challenges
Table 147. Glutamate Antagonist Market Restraints
Table 148. Research Programs/Design for This Report
Table 149. Key Data Information from Secondary Sources
Table 150. Key Data Information from Primary Sources
List of Figures
Figure 1. Product Picture of Glutamate Antagonist
Figure 2. Global Glutamate Antagonist Market Value Comparison by Type (2024-2034) & (US$ Million)
Figure 3. Global Glutamate Antagonist Market Share by Type in 2022 & 2029
Figure 4. Ionic Product Picture
Figure 5. Non Ionic Product Picture
Figure 6. Global Glutamate Antagonist Market Value Comparison by Application (2024-2034) & (US$ Million)
Figure 7. Global Glutamate Antagonist Market Share by Application in 2022 & 2029
Figure 8. Hospitals
Figure 9. Clinics
Figure 10. Laboratory
Figure 11. Others
Figure 12. Global Glutamate Antagonist Revenue, (US$ Million), 2018 VS 2022 VS 2029
Figure 13. Global Glutamate Antagonist Market Size (2018-2029) & (US$ Million)
Figure 14. Global Glutamate Antagonist Sales (2018-2029) & (K Units)
Figure 15. Global Glutamate Antagonist Average Price (US$/Unit) & (2018-2029)
Figure 16. Glutamate Antagonist Report Years Considered
Figure 17. Glutamate Antagonist Sales Share by Manufacturers in 2022
Figure 18. Global Glutamate Antagonist Revenue Share by Manufacturers in 2022
Figure 19. The Global 5 and 10 Largest Glutamate Antagonist Players: Market Share by Revenue in 2022
Figure 20. Glutamate Antagonist Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2018 VS 2022
Figure 21. Global Glutamate Antagonist Market Size by Region (US$ Million): 2018 VS 2022 VS 2029
Figure 22. North America Glutamate Antagonist Sales Market Share by Country (2018-2029)
Figure 23. North America Glutamate Antagonist Revenue Market Share by Country (2018-2029)
Figure 24. United States Glutamate Antagonist Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 25. Canada Glutamate Antagonist Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 26. Europe Glutamate Antagonist Sales Market Share by Country (2018-2029)
Figure 27. Europe Glutamate Antagonist Revenue Market Share by Country (2018-2029)
Figure 28. Germany Glutamate Antagonist Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 29. France Glutamate Antagonist Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 30. U.K. Glutamate Antagonist Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 31. Italy Glutamate Antagonist Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 32. Russia Glutamate Antagonist Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 33. Asia Pacific Glutamate Antagonist Sales Market Share by Region (2018-2029)
Figure 34. Asia Pacific Glutamate Antagonist Revenue Market Share by Region (2018-2029)
Figure 35. China Glutamate Antagonist Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 36. Japan Glutamate Antagonist Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 37. South Korea Glutamate Antagonist Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 38. India Glutamate Antagonist Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 39. Australia Glutamate Antagonist Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 40. China Taiwan Glutamate Antagonist Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 41. Southeast Asia Glutamate Antagonist Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 42. Latin America Glutamate Antagonist Sales Market Share by Country (2018-2029)
Figure 43. Latin America Glutamate Antagonist Revenue Market Share by Country (2018-2029)
Figure 44. Mexico Glutamate Antagonist Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 45. Brazil Glutamate Antagonist Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 46. Argentina Glutamate Antagonist Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 47. Middle East & Africa Glutamate Antagonist Sales Market Share by Country (2018-2029)
Figure 48. Middle East & Africa Glutamate Antagonist Revenue Market Share by Country (2018-2029)
Figure 49. Turkey Glutamate Antagonist Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 50. Saudi Arabia Glutamate Antagonist Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 51. UAE Glutamate Antagonist Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 52. Global Sales Market Share of Glutamate Antagonist by Type (2018-2029)
Figure 53. Global Revenue Market Share of Glutamate Antagonist by Type (2018-2029)
Figure 54. Global Glutamate Antagonist Price (US$/Unit) by Type (2018-2029)
Figure 55. Global Sales Market Share of Glutamate Antagonist by Application (2018-2029)
Figure 56. Global Revenue Market Share of Glutamate Antagonist by Application (2018-2029)
Figure 57. Global Glutamate Antagonist Price (US$/Unit) by Application (2018-2029)
Figure 58. Glutamate Antagonist Value Chain
Figure 59. Glutamate Antagonist Production Process
Figure 60. Channels of Distribution (Direct Vs Distribution)
Figure 61. Distributors Profiles
Figure 62. Bottom-up and Top-down Approaches for This Report
Figure 63. Data Triangulation
Figure 64. Key Executives Interviewed